UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington D.C. 20549

 

 

FORM 8-K

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): June 2, 2015

 

 

CYTOSORBENTS CORPORATION

(Exact name of registrant as specified in its charter)

 

 

Delaware   000-51038   98-0373793
(State or other jurisdiction of incorporation)   (Commission File Number)   (I.R.S. Employer Identification No.)
 

7 Deer Park Drive, Suite K,

Monmouth Junction, New Jersey

 

08852

(Address of principal executive offices) (Zip Code)
           

 

 

Registrant’s telephone number, including area code: (732) 329-8885

 

Not Applicable

(Former name or former address, if changed since last report.)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

  ¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

  ¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

  ¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

  ¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 
 

 

Item 5.07 Submission of Matters to a Vote of Security Holders


CytoSorbents Corporation (the “Company”) held its Annual Meeting of Stockholders (the “Annual Meeting”) on June 2, 2015. The proposals submitted by the Company’s Board of Directors to a vote of stockholders at the Annual Meeting, and the final results of the voting on each proposal, are noted below.

 

Proposal No. 1 — Election of Directors

 

The following nominees were elected by stockholders to serve on the Company’s Board of Directors for a term of one year each:

 

Nominees  For   Against   Broker Non-Votes 
Phillip Chan   11,368,413    40,138    8,485,960 
Al W. Kraus   10,955,447    453,104    8,485,960 
Edward R. Jones   11,371,757    36,794    8,485,960 
James Gunton   11,364,373    44,178    8,485,960 
Alan D. Sobel   11,373,895    34,656    8,485,960 
                

 

Proposal No. 2 — Advisory Vote to Approve Compensation of the Named Executive Officers

 

The stockholders approved, on an advisory basis, the compensation of the named executive officers as disclosed in the Company’s proxy statement for the 2015 Annual Meeting of Stockholders. The result of the advisory vote is set forth below:

 

For   Against   Abstain   Broker Non-Votes 
 11,118,694    139,894    149,963    8,485,960 

 

 
 

 

Proposal No. 3 — Advisory Vote on Frequency of Advisory Vote on Compensation of Named Executive Officers

 

The stockholders approved, on an advisory basis, to hold an advisory vote on the compensation of the Company’s named executive officers every three years. The result of the advisory vote on the frequency of future advisory votes on the compensation of named executive officers is set forth below:

 

1 Year   2 Years   3 Years   Abstain   Broker Non-Votes 
 880,732    219,462    10,221,378    86,979    8,485,960 

 

Proposal No. 4 — Ratification of the Appointment of Independent Registered Public Accounting Firm

 

The stockholders ratified the appointment of WithumSmith+Brown, PC as the independent registered public accounting firm to audit the Company’s 2015 consolidated financial statements. The voting results on the proposal were as follows:

 

For   Against   Abstain 
 19,682,979    97,465    114,067 

 

 
 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Dated: June 4, 2015 CYTOSORBENTS CORPORATION
     
  By: /s/ Dr. Phillip P. Chan
  Name: Dr. Phillip P. Chan
  Title:

President and

Chief Executive Officer